| Name | Title | Contact Details |
|---|
ExL Pharma is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Headquartered in Malvern, Pennsylvania, Encore Dermatology is a privately held fully integrated dermatology company with a mission committed to delivering innovative prescription therapies and medical devices to dermatologists focusing on customer service and improving the quality-of-life of patients.
A happier, healthier you is our goal. Kitsap Mental Health Services provides comprehensive, compassionate and people-centered care.
Redmond and Greer Pharmacy Supply is a new and motivated corporation with many iconic brands in our portfolio. Our company began much like many independent pharmacies do, as a family business. Over a short time, the family business evolved into what is now one of the nation`s largest suppliers of niche market prescription medications and related products. Growing is at our heart and products are always changing use our expertise to make sure you`re on the forefront of these new products. Redmond and Greer Pharmacy Supply is a division of The Coney Consulting Group, LLC Our MISSION Our focus is providing value to our customers. We drive value to independent pharmacies by navigating the constantly changing business environment and keeping them in front of new products and profitable opportunities. Our VISION To be the preferred secondary wholesaler to the independent pharmacy market. Our VALUES Being pharmacist owned, we are highly focused on growing the business of the independent pharmacy. Our customers deserve the best, and to provide the best, we deliver all the tools a pharmacy needs to succeed – comprehensive product knowledge, access to pharmaceutical drugs at the best price, and a team that puts service and compliance above all else.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (“AUD using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.